![]() |
|
|
Vol. 301, Issue 1, 266-276, April 2002
Division on Substance Abuse, New York State Psychiatric Institute
and Department of Psychiatry, College of Physicians and Surgeons of
Columbia University, New York, New York
Several sources indicate that intravenously administered buprenorphine
may have significant abuse liability in humans. The present study
evaluated the reinforcing effects of intravenously administered
buprenorphine (0, 2, and 8 mg) in detoxified heroin-dependent participants during a 7.5-week inpatient study. Participants
(n = 6) were detoxified from heroin over a 1.5-week
period immediately after admission. Testing subsequently occurred in
three 2-week blocks. During the first week of each 2-week block, the
reinforcing effects of buprenorphine were evaluated. Participants first
received a dose of buprenorphine and $20 and then were given either the opportunity to self-administer the dose or $20 during choice sessions. During the second week of each 2-week block, the direct effects of
heroin were measured to evaluate potential long-lasting antagonist effects of buprenorphine. Progressive ratio break-point values were
significantly higher after 2 and 8 mg of buprenorphine compared with
placebo. Correspondingly, several positive subjective ratings increased
after administration of active buprenorphine relative to placebo.
Although there were few differences in peak effects produced by 2 versus 8 mg of buprenorphine, the higher buprenorphine dose generally
produced longer-lasting effects. Heroin also produced dose-related
increases in several subjective effects. Peak ratings produced by
heroin were generally higher than peak ratings produced by
buprenorphine. There was little evidence of residual antagonism produced by buprenorphine. These results demonstrate that buprenorphine served as a reinforcer under these conditions, and that it may have
abuse liability in nonopioid-dependent individuals who abuse heroin.
This article has been cited by other articles:
![]() |
S. D. Comer, M. A. Sullivan, and E. A. Walker Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Fudala, T. P. Bridge, S. Herbert, W. O. Williford, C. N. Chiang, K. Jones, J. Collins, D. Raisch, P. Casadonte, R. J. Goldsmith, et al. Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone N. Engl. J. Med., September 4, 2003; 349(10): 949 - 958. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Comer and E. D. Collins Self-Administration of Intravenous Buprenorphine and the Buprenorphine/Naloxone Combination by Recently Detoxified Heroin Abusers J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 695 - 703. [Abstract] [Full Text] [PDF] |
||||